Spanish biopharmaceutical company Biofabri and nonprofit scientific research organization IAVI announced today that the first ...

Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of ...

Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of ...

A new mRNA vaccine against tuberculosis (TB) is showing favorable results in preclinical trials. With only one currently ...

Innovative research at Weill Cornell Medicine introduces engineered mycobacteria strains with 'kill switches' for safer TB ...

A new LNP-mRNA vaccine significantly boosts immune response and enhances BCG protection against tuberculosis, offering a ...

Researchers have engineered two mycobacterial strains with built-in kill switches that trigger self-destruction after immune ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials.

The platform can be harnessed for TB, potentially improving protection and durability of immunity in a way that traditional ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...

Australian researchers have developed a new mRNA vaccine for tuberculosis, showing effective results in mice. The vaccine ...